PMID- 38174379
OWN - NLM
STAT- MEDLINE
DCOM- 20240220
LR  - 20240220
IS  - 1744-8328 (Electronic)
IS  - 1473-7140 (Linking)
VI  - 24
IP  - 1-2
DP  - 2024 Jan-Feb
TI  - Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance 
      therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with 
      BRCA mutational status: a systematic review and network meta-analysis.
PG  - 59-69
LID - 10.1080/14737140.2023.2298832 [doi]
AB  - BACKGROUND: Poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors 
      (PARPi) treatment for ovarian cancer (OC) are ever-changing. This study aimed to 
      compare the efficacy and overall safety of available PARPi as maintenance therapy 
      for BRCA mutation status in patients with newly diagnosed and platinum-sensitive 
      recurrent (PSR) OC patients. RESEARCH DESIGN AND METHODS: Relevant RCTs were 
      systematically retrieved from PubMed and Embase until 31 May 2022. 
      Progression-free survival (PFS) and overall survival (OS) based on BRCA mutation 
      status and adverse events (AEs) regardless of mutation were efficacy and safety 
      endpoints. RESULTS: In newly diagnosed BRCAm-OC patients, olaparib (HR: 0.33; 95% 
      confidence interval [CI]: 0.25, 0.43) and other PARPis [niraparib (HR: 0.40; 95% 
      CI: 0.29, 0.55), rucaparib (HR: 0.40; 95% CI: 0.21, 0.76) and veliparib (HR: 
      0.44; 95% CI: 0.28, 0.69)] had a statistically significant effect on PFS versus 
      placebo. In BRCAm-PSROC patients, Olaparib exhibited significant benefit (HR: 
      0.69; 95% CI: 0.54, 0.88) for OS compared to other PARPis. In BRCAwt-PSR OC 
      patients, Olaparib showed a favorable OS benefit than other PARPis (HR: 0.84; 95% 
      CI: 0.57,1.22). Overall, safety profile of all PARPis was acceptable. CONCLUSION: 
      All PARPis showed significant benefit, with olaparib showing greater benefit in 
      newly diagnosed and PSR OC women. REGISTRATION: CRD42021288932.
FAU - Zhou, Shulin
AU  - Zhou S
AD  - Department of Gynaecology, The First Affiliated Hospital with Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Jiang, Yi
AU  - Jiang Y
AD  - Department of Gynaecology, The First Affiliated Hospital with Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Luo, Chengyan
AU  - Luo C
AD  - Department of Gynaecology, The First Affiliated Hospital with Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Yuan, Lin
AU  - Yuan L
AD  - Department of Gynaecology, The First Affiliated Hospital with Nanjing Medical 
      University, Nanjing, Jiangsu, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20240212
PL  - England
TA  - Expert Rev Anticancer Ther
JT  - Expert review of anticancer therapy
JID - 101123358
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 0 (Poly(ADP-ribose) Polymerase Inhibitors)
RN  - EC 2.4.2.30 (Poly(ADP-ribose) Polymerases)
RN  - 681HV46001 (Ribose)
SB  - IM
MH  - Female
MH  - Humans
MH  - Adenosine Diphosphate/therapeutic use
MH  - Carcinoma, Ovarian Epithelial/drug therapy
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - Network Meta-Analysis
MH  - *Ovarian Neoplasms/drug therapy/genetics
MH  - *Poly(ADP-ribose) Polymerase Inhibitors/adverse effects
MH  - Poly(ADP-ribose) Polymerases
MH  - Ribose/therapeutic use
OTO - NOTNLM
OT  - Network meta-analysis
OT  - ovarian cancer
OT  - overall survival
OT  - platinum-sensitive recurrent ovarian cancer
OT  - poly(ADP-ribose) polymerase inhibitor
OT  - progression-free survival
EDAT- 2024/01/04 11:44
MHDA- 2024/02/13 12:45
CRDT- 2024/01/04 04:27
PHST- 2024/02/13 12:45 [medline]
PHST- 2024/01/04 11:44 [pubmed]
PHST- 2024/01/04 04:27 [entrez]
AID - 10.1080/14737140.2023.2298832 [doi]
PST - ppublish
SO  - Expert Rev Anticancer Ther. 2024 Jan-Feb;24(1-2):59-69. doi: 
      10.1080/14737140.2023.2298832. Epub 2024 Feb 12.